摘要
Abstract
Objective:To explore the efficacy of Nicordil combined with Trimetazidine in the treatment of coronary heart disease-angina pectoris(CHD-AP).Methods:A total of 78 CHD-AP patients admitted to Department of Emergency Juxian County People's Hospital from October 2021 to February 2023 were selected as the study objects.They were divided into a control group and a study group according to random number table method,with 39 cases in each group.The control group was treated with Nicodil Tablets,the Study group was treated with Trimetazidine Hydrochloride Tablets on the basis of t control group.The total effective rate,incidence of angina pectoris,inflammation indexes and the occurrence of adverse reactions were compared between the two groups.Results:The total effective rate of the study group was 92.31%,which was higher than 74.36%in the control group,the difference was statistically significant(P<0.05).After treatment,the frequency of angina pectoris in the study group was less than that in the control group,the duration of angina pectoris was shorter than that in the control group,with statistical significances(P<0.05).After treatment,the tumor necrosis factor-α,highly sensitive C-reactive protein,interleukin-6,interleukin-8 of the two groups were lower than before treatment,the study group were lower than those in the control group,with statistical significances(P<0.05).The incidence of adverse reactions in the study group was 15.38%,compared with 7.69%in the control group,the difference was not statistically significant(P>0.05).Conclusion:Nicordil combined with Trimetazidine is effective in the treatment of CHD-AP patients,which can effectively reduce the attack number of angina pectoris,shorten the duration of angina pectorts,reduce the inflammatory substances in serum,has certain safety.关键词
冠心病心绞痛/尼可地尔/曲美他嗪/临床疗效/炎症Key words
Coronary heart disease-angina pectoris/Nicorandil/Trimetazidine/Clinical efficacy/Inflammation分类
医药卫生
